Personal record-keeping and educational reference. 18+. The app does not recommend substances, doses or treatment, or determine whether a substance is safe, approved or appropriate for you. Consult a qualified healthcare professional about decisions involving your health.
‹ Library

Cagrilintide

GLP-1 / MetabolicResearch Use Only

Also known as: AM833, long-acting amylin analog

An amylin analog that adds fullness signalling; often paired with a GLP-1 for stronger appetite control.

Dosing quick reference

research reference
Starting dose
0.6 mg once weekly
Frequency
Once weekly
Typical range
0.6–4.5 mg per week
Cycle
12–16 weeks
Titration (step-up)
Wk 1–2: 0.6 → Wk 3–4: 1.2 → Wk 5–6: 2.4 → Wk 7+: 4.5 mg
Half-life
~7–8 days
Route
Subcutaneous (research)
Common use
Metabolic and appetite-regulation research
Common vial sizes
5 mg · 10 mg
Storage
Store lyophilized powder refrigerated (2–8°C) and protected from light; once reconstituted, keep refrigerated and use within the timeframe supported by stability data.
Stacking notes
Frequently referenced alongside semaglutide as a combined amylin/GLP-1 research approach (sometimes described as CagriSema). Combining metabolic agents compounds gastrointestinal effects.

Reported side effects

NauseaReduced appetiteGastrointestinal upset
Regulatory note: Investigational; not approved in Canada or the US. Under clinical development, often studied in combination with semaglutide. Research-grade material is not for human use.
Calculate a dose →Cagrilintide on The Peptide Guide →Deeper research reference: literature dose ranges, storage and handling, and where to source in Canada.

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Research-only labeling does not establish that a substance is safe, approved or appropriate for personal use. Consult a qualified healthcare professional about health decisions.